Gemifloxacin mesylate

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-B1050 210353-53-0 C ₁₉ H ₂₄ FN ₅ O ₇ S 485.49 Bacterial; Antibiotic; DNA/RNA Synthesis; Topoisomerase Anti-infection; Cell Cycle/DNA Damage 4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture	$ \begin{array}{c} H_2N \\ N \\ -O \\ F \\ \hline O \\ F \\ \hline O \\ O \\$
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)	

SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg 10		
	Preparing Stock Solutions	1 mM	2.0598 mL	10.2989 mL	20.5977 mL	
		5 mM	0.4120 mL	2.0598 mL	4.1195 mL	
		10 mM	0.2060 mL	1.0299 mL	2.0598 mL	
	Please refer to the so	lubility information to select the app	propriate solvent.			
ı Vivo		1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.15 mM); Clear solution				
		2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.15 mM); Clear solution				
		3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.15 mM); Clear solution				

BIOLOGICAL ACTIVITY				
DIOLOGICALACIN				
Description	Gemifloxacin mesylate (SB-265805S; LB-20304a) is an orally active broad-spectrum quinolone antibacterial antibiotic. Gemifloxacin mesylate inhibits DNA synthesis by inhibiting DNA gyrase and Topoisomerase IV activities. Gemifloxacin mesylate has potent antibacterial activities against gram-positive bacteria in vitro efficacy study, particularly Streptococci and Staphylococci. Gemifloxacin mesylate has been used in the research of respiratory tract infections ^{[1][2][3]} .			
IC ₅₀ & Target	Quinolone			



In Vitro	Gemifloxacin has higher antibacterial activity than <u>Moxifloxacin</u> (HY-66011A) against Streptococcus pneumoniae with a MIC ₉₀ of 0.06 μg/mL ^[2] . Gemifloxacin has highly potent antibacterial activity against <u>Penicillin</u> -resistant strains of S. pneumoniae with a MIC ₉₀ of 0.03 μg/mL ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.						
In Vivo	Gemifloxacin has favorable pharmacokinetic profile in animals after oral administration ^[1] . Pharmacokinetic Parameters of Gemifloxacin in Sprague-Dawley rats and dogs ^[1] .						
	Species	A Administration	lUC ₀₋₂₄ (μ g/mL·h)	Half-life (h)	C _{max} (µg/mL)	T _{max} (h)	F (%)
	Rat	p.o.; 20 mg/kg	8.50	2.33	2.44	0.33	95.3
	Dog	p.o.; 4 mg/kg	7.55	5.12	1.34	1.13	71
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.						

REFERENCES

[1]. Hong CY. Discovery of gemifloxacin (Factive, LB20304a): a quinolone of a new generation. Farmaco. 2001 Jan-Feb;56(1-2):41-4.

[2]. Allen A, Kim I, et al. Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. Antimicrob Agents Chemother. 2001 Feb;45(2):540-5.

[3]. Erdem M, et al. Ingestion of the anti-bacterial agent, gemifloxacin mesylate, leads to increased gst activity and peroxidation products in hemolymph of Galleria mellonella l. (lepidoptera: pyralidae). Arch Insect Biochem Physiol. 2016 Dec;93(4):202-209.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA